[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576253":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":40,"responsibleParty":60,"collaborators":64,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":11,"enrollmentInfo":81,"targetDuration":11,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":92,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Aveiro University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"COUGH-LESS Programme","EXPERIMENTAL",null,[13],"Behavioral: Non-pharmacological cough control therapy",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Group","SHAM_COMPARATOR",[18],"Behavioral: Healthy lifestyle",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"BEHAVIORAL","Non-pharmacological cough control therapy","Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about chronic cough, introduction to cough suppression and goal setting. Session 2 will cover education about chronic cough in ILD, cough triggers and training in cough suppression techniques. Session 3 will focus on hydration techniques, laryngeal hygiene, and breathing exercises to control coughing. Session 4 will reinforce all aspects of non-pharmacological cough control treatment, and session 5 will explore the sustainability of cough control strategies after the program using real-life case scenarios.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Healthy lifestyle","Over seven weeks (1 session per week, except session 5, which will be 2 weeks after session 4) using a one-on-one hybrid model. In session 1, participants will receive general education about exercise and physical activity. Session 2 will cover education about diet. Session 3 will focus on stress management. Session 4 will cover relaxation techniques, and session 5 will reinforce all aspects previously considered.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Ana L Oliveira, PhD","CONTACT","00351913937469","alao@ua.pt",{"name":36,"role":32,"phone":37,"phoneExt":38,"email":39},"Alda Marques, PhD","00351234372462","27121","amarques@ua.pt",[41],{"facility":5,"status":11,"city":42,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Aveiro","Portugal","PT",{"type":46,"coordinates":47},"Point",[48,49],-8.64643,40.64575,{"lat":49,"lon":48},[52,55,57,58],{"name":53,"role":32,"phone":54,"phoneExt":11,"email":34},"Ana L Oliveira","+351913937469",{"name":56,"role":32,"phone":11,"phoneExt":11,"email":11},"Ana S Grave, MSc",{"name":36,"role":32,"phone":11,"phoneExt":11,"email":11},{"name":59,"role":32,"phone":11,"phoneExt":11,"email":11},"Diogo Tecelão, MSc",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof Ana Oliveira","Assistant professor",[65,67,69],{"name":66,"class":6},"Fundação para a Ciência e a Tecnologia",{"name":68,"class":6},"Centro Hospitalar do Baixo Vouga",{"name":70,"class":6},"Centro Hospitalar de Entre o Douro e Vouga","100576253","chronic-cough-management-in-interstitial-lung-disease-100576253",false,"NCT06782893","Chronic COUGH Management in Interstitial Lung DisEase","COUGH-LESS: Chronic COUGH Management in Interstitial Lung DisEase - Non-pharmacological Strategies and Solutions","COUGH-LESS","Inclusion Criteria:\n\ni) Adults (\\>18 years old) ii) Clinical diagnosis of ILD iii) Presenting chronic cough (\\> 8 weeks of duration) iv) People with access to a virtual meeting platform\u002Ftelephone.\n\nExclusion Criteria:\n\ni) Self-reports of moderate or large sputum production (\\> 2 tablespoons); ii) Actual or suspected exacerbation of the respiratory condition in the last month; iii) Upper respiratory tract infection (e.g. cold); iv) Use of angiotensin-converting enzyme inhibitor medication; v) Changes in prescribed medication in the last month; vi) Signs of cognitive impairment or significant cardiovascular, neurological and\u002For musculoskeletal disease that may limit participation in the program; vii) Inability to read or speak Portuguese; viii) Inability to provide informed consent.","ALL","18 Years",{"count":82,"type":83},60,"ESTIMATED","INTERVENTIONAL",[86],"NA","Interstitial Lung Disease (ILD) includes chronic, disabling and progressive respiratory conditions marked by lung inflammation and fibrosis. The quality of life and functionality of people with ILD is affected by a plethora of debilitating symptoms such as dyspnoea fatigue and cough. Among them, chronic cough (a cough lasting more than 8 weeks) reigns as one of the most prevalent and challenging, despite receiving far less attention from researchers than other symptoms. Chronic cough affects up to 8 out of 10 individuals with ILD and it is associated with a worse prognosis, mortality, and the need for lung transplantation. This condition showed a significant impact in people's life (e.g., urinary incontinence, speech interferences, depression, chest pain, couples sleeping in separate bedrooms, avoidance of public areas, reduced social interaction, and work absenteeism), further contributing to the decreased health-related quality of life experienced by this population. Managing chronic cough is, therefore, urgently needed. The general aim of this study is to explore the effects of a non-pharmacological cough control treatment on cough-related quality of life in people with ILD. The specific aims of this study are: i) to explore short- and mid-term effects of the non-pharmacological cough control treatment on cough related outcomes (e.g., cough frequency and intensity, dyspnoea, fatigue, cough self-efficacy, health-related quality of life and emotional status); ii) to identify (if any) adverse effects of this therapy.",[89,90],"Interstitial Lung Disease","Chronic Cough",[90,89,22],"NOT_YET_RECRUITING","2025-01-14",{"date":95,"type":96},"2025-01-20","ACTUAL",{"date":98,"type":83},"2027-12-20",{"date":100,"type":83},"2028-07-30",{"name":5,"class":6},1]